Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-04-09EMA Withdrawn: Copiktra (duvelisib) — Secura Bio Limited
The European Medicines Agency has withdrawn the marketing authorization for Copiktra (duvelisib) from Secura Bio Limited; the drug for chron…
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 study investigating the sequencing of pirtobrutinib after progression on first-line acalabrutinib in adults with chronic lymphocyt…
-
CLINICAL_TRIALS withdrawal · 2025-05-22Clinical Trial Update: Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL [Phase 2]
A Phase 2 trial studying Copanlisib in combination with Ibrutinib or Acalabrutinib for relapsed/refractory Chronic Lymphocytic Leukemia has …
-
CLINICAL_TRIALS withdrawal · 2025-05-16Clinical Trial Update: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A clinical trial evaluating a time-limited use of Ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…
-
CLINICAL_TRIALS withdrawal · 2025-02-28Clinical Trial Update: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation [Phase 1]
Phase 1 trial of ipilimumab, ibrutinib, and nivolumab for chronic lymphocytic leukemia and Richter transformation has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]
A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: Cardiotoxicities in Patients Receiving BTKi
A clinical trial evaluating cardiotoxicities in patients receiving Bruton's tyrosine kinase inhibitors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS withdrawal · 2024-04-19Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) [Phase 2, Phase 3]
Clinical trial ULTRA-V (Ublituximab with Umbralisib ± Venetoclax) in CLL/SLL has been terminated, with results posted.
-
CLINICAL_TRIALS withdrawal · 2024-04-02Clinical Trial Update: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies [Phase 3]
Phase 3 trial comparing lisocabtagene maraleucel vs investigator's choice in adult relapsed/refractory CLL/SLL has been withdrawn.
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
-
EMA withdrawal · 2019-05-10EMA Withdrawn: Arzerra (ofatumumab) — Novartis Europharm Ltd
EMA has withdrawn Arzerra (ofatumumab) from the market in Europe.
-
CLINICAL_TRIALS withdrawal · 2019-01-25Clinical Trial Update: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. [Phase 1]
A Phase 1 trial evaluating obinutuzumab in combination with high-dose ibrutinib for chronic lymphocytic leukemia patients with progression o…
-
CLINICAL_TRIALS withdrawal · 2018-07-30Clinical Trial Update: Safety and Activity of SNX-5422 Plus Ibrutinib in CLL [Phase 1]
Phase 1 trial investigating SNX-5422 in combination with ibrutinib in chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-04-05Clinical Trial Update: Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
A clinical trial evaluating splenic irradiation for chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-19Clinical Trial Update: Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Clinical trial NCT01069432, a protocol to obtain blood for discovery of biomarkers and potential therapeutic targets in chronic lymphocytic …
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]
A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…
-
CLINICAL_TRIALS withdrawal · 2017-06-12Clinical Trial Update: Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) [Phase 1]
A Phase 1 trial evaluating autologous ROR1R-CAR-T cells for chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-28Clinical Trial Update: Evaluation of the Immune Restoration Potential Of Lenalidomide [Phase 2]
A Phase 2 trial evaluating lenalidomide for immune restoration in Chronic Lymphocytic Leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-05Clinical Trial Update: Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation [Phase 2]
This clinical trial update reports that the Phase 2 study of Sotrastaurin acetate for relapsed or refractory chronic lymphocytic leukemia, s…
-
CLINICAL_TRIALS withdrawal · 2016-12-06Clinical Trial Update: Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Phase 2]
A Phase 2 trial evaluating urelumab in combination with rituximab for relapsed/refractory or high-risk untreated chronic lymphocytic leukemi…
-
CLINICAL_TRIALS withdrawal · 2016-07-26Clinical Trial Update: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor [Phase 1]
A Phase 1 study of the combination of duvelisib and venetoclax in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lym…
-
CLINICAL_TRIALS withdrawal · 2016-03-02Clinical Trial Update: Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]
Phase 1 trial of MT-3724 for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma has been withdrawn; no results are reported…